Serum Biomarkers for Colorectal Cancer Detection

用于结直肠癌检测的血清生物标志物

• 批准号: 7826919
• 负责人: MICHAEL A TAINSKY
• 金额: $ 16.54万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-05 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7826919
• 关键词: Antibodies; Antigens; Benign; Binding; Biological Assay; Biological Markers; Biological Neural Networks; Blood Tests; Cancer Detection; Cancer Patient; Cancerous; Characteristics; Clinical; Colon Carcinoma; Colorectal Cancer; Comorbidity; Complementary DNA; DNA Sequence; Data; Databases; Detection; Development; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Diagnostic tests; Differentiation Antigens; Early Diagnosis; Family history of; Gastrointestinal Diseases; Generations; Goals; Immunoglobulin G; Individual; Inflammatory Bowel Diseases; Laboratories; Lung; Machine Learning; Malignant Neoplasms; Methods; Non-Malignant; Patients; Population Study; Prevention strategy; Printing; Proteins; Public Health; Research; Sampling; Screening procedure; Sensitivity and Specificity; Serum; Subgroup; Survival Rate; Symptoms; Techniques; Technology; Testing; Time; Work; clinical practice; cohort; demographics; gastrointestinal; improved; new technology; racial and ethnic; therapeutic target; tumor

DESCRIPTION (provided by applicant): When cancer is identified at the earliest stages, cancer survival rates dramatically increase and therefore diagnostic screening tests that can detect early stage cancer are crucial. The overall goal of our research is to develop such an early detection screening test. We intend to prospectively accrue a large well-defined independent cohort of colorectal cancer (CRC) cases where we collect extensive data on this cohort at the time of diagnosis. We will generate a comprehensive database that includes data on demographics, personal and family history, tumor characteristics, and comorbidities. Our preliminary research efforts have been to develop a detection assay utilizing the sera of our discovery cohort of CRC patients and healthy controls. We have developed a high throughput method to isolated cDNA clones of antigens which can be used to identify cancer cases by detecting the presence of auto-antibodies to tumor proteins in the serum of the test subject. Our first aim is to identify the minimal number of antigen clones that are critical in distinguishing sera from patients with colorectal cancer from healthy controls utilizing our initial discovery cohort. We will eliminate antigen clones from our discovery set of 3800 clones that react with sera from patients with other cancers, benign gastrointestinal conditions, duplicates or do not react with any CRC sera. Our second aim is to determine the test characteristics (sensitivity, specificity, accuracy) on these newly selected antigen markers for distinguishing colorectal cancer cases using newly acquired sera samples not previously used in the development of the marker set. Lastly, we intend to determine the test characteristics of these antigen markers on a large independent well-defined cohort of colorectal cancer patients and healthy controls. In addition, due to the size, racial/ethnic makeup of the study population, and captured patient data, we will be able to evaluate the expression of these markers in relationship to important subgroups.

描述（由申请人提供）：当癌症在最早阶段被发现时，癌症生存率会显着增加，因此可以检测早期癌症的诊断筛查测试至关重要。我们研究的总体目标是开发这样一种早期检测筛查测试。我们打算前瞻性地积累一个大型的明确定义的独立的结直肠癌（CRC）病例队列，我们在诊断时收集有关该队列的广泛数据。我们将建立一个全面的数据库，其中包括人口统计学、个人和家族史、肿瘤特征和合并症的数据。我们的初步研究工作是利用我们发现的CRC患者和健康对照组的血清开发检测测定法。我们已经开发了一种高通量方法来分离抗原的cDNA克隆，其可用于通过检测测试受试者血清中肿瘤蛋白的自身抗体的存在来鉴定癌症病例。我们的第一个目标是确定最小数量的抗原克隆，这些克隆对于利用我们的初始发现队列区分来自结直肠癌患者的血清和健康对照至关重要。我们将从我们的3800个克隆的发现集中排除与来自患有其他癌症、良性胃肠道疾病、重复或不与任何CRC血清反应的患者的血清反应的抗原克隆。我们的第二个目的是确定这些新选择的抗原标志物的测试特性（灵敏度，特异性，准确性），用于区分结直肠癌病例，使用新获得的血清样品，以前没有使用的标记集的发展。最后，我们打算确定这些抗原标志物在结直肠癌患者和健康对照的大型独立明确队列中的测试特征。此外，由于研究人群的规模、人种/种族构成和采集的患者数据，我们将能够评价这些标志物与重要亚组的关系。